Profile data is unavailable for this security.
About the company
hVIVO plc is a United Kingdom-based specialist contract research organization (CRO). The Company is engaged in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. It operates through medical and scientific research services segment. It provides end-to-end early clinical development services to its client base, which includes global biopharma companies. It offers a portfolio of approximately 11+ human challenge models to test a range of infectious and respiratory disease products, challenge agent manufacturing, specialist drug development, and clinical consultancy services. It offers additional clinical field trial services, such as Challenge Models, Pre-clinical, CMC & PK, Study Design & Protocol Development, Ethics & Regulatory, Phase I & II, Volunteer/Patient Recruitment, Clinical site, Monitoring, Biometrics, and Medical Writing. Its subsidiaries include hVIVO Holdings Limited, Open Orphan DAC, hVIVO Inc., and others.
- Revenue in GBP (TTM)64.38m
- Net income in GBP17.45m
- Incorporated2011
- Employees274.00
- LocationhVIVO PLC42 New RoadLONDON E1 2AXUnited KingdomGBR
- Phone+44 289 073 7900
- Websitehttps://hvivo.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Poolbeg Pharma PLC | 0.00 | -4.38m | 43.25m | 8.00 | -- | 3.47 | -- | -- | -0.0088 | -0.0088 | 0.00 | 0.0249 | 0.00 | -- | -- | 0.00 | -29.11 | -- | -30.18 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 16.11 | -- | -- | -- |
| Futura Medical PLC | 8.40m | -3.75m | 98.43m | 12.00 | -- | 12.58 | -- | 11.72 | -0.0126 | -0.0126 | 0.0272 | 0.0259 | 0.8538 | 5,710.27 | 7.20 | 699,850.80 | -38.14 | -79.25 | -47.43 | -127.22 | 67.70 | -- | -44.68 | -914.37 | 3.75 | -- | 0.00 | -- | -- | -- | -11.40 | -- | 219.68 | -- |
| Scancell Holdings Plc | 0.00 | -5.86m | 123.17m | 61.00 | -- | -- | -- | -- | -0.0068 | -0.0068 | 0.00 | -0.0038 | 0.00 | -- | -- | 0.00 | -23.24 | -31.66 | -32.48 | -37.66 | -- | -- | -- | -822.37 | -- | -- | 1.21 | -- | -100.00 | -- | 50.91 | -- | 131.54 | -- |
| 4Basebio PLC | 596.00k | -9.84m | 178.07m | -- | -- | -- | -- | 298.77 | -0.7843 | -0.7843 | 0.0476 | -0.4075 | 0.0508 | 0.6453 | 10.64 | -- | -83.78 | -- | -97.43 | -- | 69.63 | -- | -1,650.67 | -- | 2.53 | -18.44 | 1.51 | -- | 88.81 | -- | -48.83 | -- | -- | -- |
| Avacta Group Plc | 22.62m | -25.89m | 179.27m | 154.00 | -- | 3.71 | -- | 7.93 | -0.0867 | -0.0867 | 0.075 | 0.1334 | 0.2555 | 4.63 | 3.15 | 146,876.60 | -29.24 | -- | -61.16 | -- | 42.08 | -- | -114.45 | -- | 1.21 | -1.23 | 0.3875 | -- | 140.83 | -- | 32.54 | -- | -- | -- |
| hVIVO PLC | 64.38m | 17.45m | 200.06m | 274.00 | 10.99 | 4.91 | 9.68 | 3.11 | 0.0252 | 0.0252 | 0.0932 | 0.0565 | 0.9242 | -- | 4.25 | 234,974.50 | 25.04 | -0.643 | 46.68 | -1.29 | -- | -- | 27.10 | -0.765 | 1.60 | -- | 0.2530 | -- | 15.61 | 35.40 | 2,176.68 | -- | 136.55 | -- |
| Bioventix PLC | 13.60m | 8.67m | 208.79m | 16.00 | 24.50 | 18.26 | 23.76 | 15.36 | 1.63 | 1.63 | 2.56 | 2.19 | 1.09 | 1.53 | 2.54 | 849,780.60 | 69.72 | 56.43 | 79.03 | 61.01 | 93.75 | 92.64 | 63.73 | 65.08 | 6.69 | -- | 0.00 | 84.49 | 9.36 | 7.93 | 9.10 | 8.13 | -37.12 | 20.03 |
| Allergy Therapeutics plc | 53.26m | -50.22m | 231.17m | 635.00 | -- | 8.74 | -- | 4.34 | -0.0266 | -0.0266 | 0.017 | 0.0056 | 0.7571 | 2.21 | 4.92 | 83,870.87 | -71.39 | -11.59 | -102.10 | -15.15 | 52.54 | 70.08 | -94.29 | -11.78 | 0.9281 | -7.93 | 0.2713 | -- | -18.11 | -2.71 | -212.65 | -- | 16.41 | -- |
| Faron Pharmaceuticals Oy | 0.00 | -26.45m | 231.25m | 34.00 | -- | 200.39 | -- | -- | -0.3179 | -0.3179 | 0.00 | 0.011 | 0.00 | -- | -- | 0.00 | -130.90 | -213.06 | -443.92 | -963.12 | -- | -- | -- | -- | -- | -5.99 | 0.9022 | -- | -- | -- | -7.71 | -- | -16.05 | -- |
| Puretech Health PLC | 356.82k | -62.87m | 359.33m | 90.00 | -- | 1.49 | -- | 1,007.04 | -0.2294 | -0.2294 | 0.0013 | 1.01 | 0.0007 | -- | 0.2252 | 3,964.64 | -14.13 | 4.92 | -16.35 | 5.94 | -- | -- | -19,222.22 | 352.67 | -- | -- | 0.0728 | 0.00 | -78.68 | -30.64 | -30.47 | -- | -44.10 | -- |
| Oxford BioMedica plc | 97.28m | -142.02m | 405.64m | 834.00 | -- | 6.12 | -- | 4.17 | -1.44 | -1.44 | 0.9642 | 0.6292 | 0.3012 | 4.09 | 4.21 | 136,252.10 | -51.98 | -19.60 | -66.85 | -24.68 | 36.74 | 50.74 | -172.59 | -44.38 | 2.07 | -12.47 | 0.6077 | -- | -36.04 | 6.04 | -302.20 | -- | -0.6307 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Octopus Investments Ltd.as of 23 Jul 2024 | 51.80m | 7.61% |
| JPMorgan Asset Management (UK) Ltd.as of 31 Mar 2024 | 47.89m | 7.04% |
| Link Fund Solutions Ltd.as of 30 Jun 2019 | 38.62m | 5.68% |
| Canaccord Genuity Wealth Ltd.as of 30 Apr 2024 | 27.10m | 3.98% |
| Thornbridge Investment Management LLPas of 31 Oct 2022 | 9.97m | 1.47% |
| Liontrust Investment Partners LLPas of 28 Jun 2024 | 9.40m | 1.38% |
| Janus Henderson Investors UK Ltd.as of 31 May 2024 | 8.62m | 1.27% |
| Mandarine Gestion SAas of 29 Feb 2024 | 4.27m | 0.63% |
| River Global Investors LLPas of 30 Jun 2024 | 1.11m | 0.16% |
| Lazard Asset Management LLCas of 30 Jun 2024 | 862.12k | 0.13% |
